DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01484262

Completed

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1,344

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Diabetes-related quality of life

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01484262
Org study IDNN2211-3962
Secondary IDU1111-1123-5044WHO

Timeline

Milestones

Study start2011-11-14actual
Study first posted2011-12-02estimated
Primary completion2014-10-31actual
Study completion2014-10-31actual
Last update posted2018-11-01actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients diagnosed with type 2 diabetes mellitus, currently treated with oral antidiabetics (OADs), who need treatment intensification with insulin or liraglutide due to inadequate blood glucose control.

Inclusion criteria

•Informed consent obtained before any study-related activities. (Study-related activities are any procedures related to recording of data according to the protocol)
•Patients willing and able to give signed consent on matching patient data with sick fund data
•Patients diagnosed with type 2 diabetes mellitus, currently treated with oral antidiabetic medication, who need treatment intensification with insulin or liraglutide (Victoza®) due to inadequate blood glucose control
•Patient is a member of the involved sick fund (AOK Plus)

Exclusion criteria

•Known or suspected contra-indication to the relevant study product according to current SPC
•Previous participation in this study
•History of type 1 diabetes mellitus
•Previous insulin treatment excluding emergency administration (treatment duration up to a maximum of 3 days)
•Previous treatment with liraglutide
•History of diabetic gastroparesis, diabetic precoma or diabetic ketoacidosis
•Progressive fatal disease
•Any reason in judgement of the treating physician that precludes study participation e.g. lack of compliance, safety concerns, alcohol or drug abuse
•Patients without legal capacity

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Patient-reported / QoL
1

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life)

Time frame:At the end of the observational period (52 weeks)

descriptive, improvement

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Total cost of patient's diseases

Time frame:At the end of the observational period (52 weeks)

descriptive

Secondary/protocol endpoint/low confidence

Total cost of patient education

Time frame:At the end of the observational period (52 weeks)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.